Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
22.68
+1.12 (5.19%)
At close: Jul 30, 2026, 4:00 PM EDT
22.90
+0.22 (0.97%)
After-hours: Jul 30, 2026, 7:34 PM EDT

Monte Rosa Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
1,9161,028427283375950
Market Cap Growth
461.25%140.76%50.68%-24.53%-60.50%-
Enterprise Value
1,289689.8197.4396.92159.53604.19
Last Close Price
22.6815.686.945.657.6120.42

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
44.618.315.64---
PB Ratio
3.664.411.911.581.382.73
P/TBV Ratio
3.805.592.301.621.321.47
P/FCF Ratio
--11.23---
P/OCF Ratio
--10.16---

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
30.015.581.29---
EV/FCF Ratio
--2.56---

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.070.150.170.240.160
Debt / FCF Ratio
--1.12---
Net Debt / Equity Ratio
-1.20-1.45-1.48-1.04-0.79-1.00
Net Debt / EBITDA Ratio
4.487.374.511.361.994.89
Net Debt / FCF Ratio
31.9112.29-8.672.972.055.01
Asset Turnover
0.070.280.20000
Quick Ratio
9.446.052.375.0010.5820.80
Current Ratio
9.546.122.405.0710.7920.96
Return on Equity (ROE)
-34.44%-16.94%-36.15%-60.07%-35.06%-40.35%
Return on Assets (ROA)
-24.67%-11.88%-22.65%-44.47%-31.71%-35.06%
Return on Invested Capital (ROIC)
----592.89%-394.11%-
Return on Capital Employed (ROCE)
-28.25%-16.27%-30.10%-49.94%-33.72%-39.42%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
FCF Yield
--8.90%---
Buyback Yield / Dilution
-9.92%-12.40%-43.80%-8.83%-88.91%-1548.09%
Total Shareholder Return
-9.92%-12.40%-43.80%-8.83%-88.91%-1548.09%
SEC Filings: 10-K · 10-Q